Preklinisk utveckling av MTHFD2 hämmare för behandling av cancer

Viktiga resultat som projektet gav

The overall goal for the project was to progress the development of novel cancer therapy from the preclinical to the clinical stage and enable first-in-human clinical trials of MTHFD1/2 inhibitors.

Långsiktiga effekter som förväntas

The project has successfully executed work packages and delivered milestones as described in the application, including important GLP toxicology studies that were prerequisites for the regulatory submission of the application for the clinical trials, finalisation of drug formulations, recruitment of necessary competence and compilation of documentation. The final outcome, aided by Vinnova´s support, is that a novel, promising cancer-targeting drug will be tested in clinical trials and potentially will provide new, better therapy options for the patients.

Upplägg och genomförande

To achieve the above results, we have systematically worked on -Recruiting necessary competence for all parts of the project. -Networking and approaching investors and key opinion leaders. -Contracting external CROs -Preforming necessary experimental R&D studies to support regulatory document requirements.

Externa länkar

www.one-carbon.com